These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36535758)

  • 21. Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma.
    Gao Z; Wu S; Yang Y; Sun M; Tian X; Jin X
    Invest New Drugs; 2023 Oct; 41(5):719-726. PubMed ID: 37589864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
    Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapy of biliary tract cancer.
    Chai Y
    Tumour Biol; 2016 Mar; 37(3):2817-21. PubMed ID: 26729196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
    Li YC; Li KS; Liu ZL; Tang YC; Hu XQ; Li XY; Shi AD; Zhao LM; Shu LZ; Lian S; Yan ZD; Huang SH; Sheng GL; Song Y; Liu YJ; Huan F; Zhang MH; Zhang ZL
    Front Immunol; 2022; 13():1049812. PubMed ID: 36389727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
    Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
    Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
    ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
    Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
    Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
    Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
    Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
    Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J
    JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
    Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapies in clinical development for biliary tract cancer.
    Vogel A; Bathon M; Saborowski A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):351-363. PubMed ID: 33382361
    [No Abstract]   [Full Text] [Related]  

  • 37. New Horizons for Precision Medicine in Biliary Tract Cancers.
    Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
    Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
    Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
    [No Abstract]   [Full Text] [Related]  

  • 39. Current status of immunotherapy for the treatment of biliary tract cancer.
    Takahashi R; Yoshitomi M; Yutani S; Shirahama T; Noguchi M; Yamada A; Itoh K; Sasada T
    Hum Vaccin Immunother; 2013 May; 9(5):1069-72. PubMed ID: 23376808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.